📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018)

First Author: Schuurhuis GJ

Attributed to: Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours). funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-09-801498

PubMed Identifier: 29330221

Publication URI: http://europepmc.org/abstract/MED/29330221

Type: Journal Article/Review

Volume: 131

Parent Publication: Blood

Issue: 12

ISSN: 0006-4971